Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Matrix metalloproteinase inhibitors.

P D Brown1

  • 1Department of Clinical Research, British Biotech Pharmaceuticals Ltd, Oxford OX4 5LY, UK.

Angiogenesis
|October 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

Neuro-oncology·2025
Same author

Distribution of virulence determinants among antimicrobial-resistant and antimicrobial-susceptible <i>Escherichia coli</i> implicated in urinary tract infections.

Indian journal of medical microbiology·2016
Same author

Growth of single-layer boron nitride dome-shaped nanostructures catalysed by iron clusters.

Nanoscale·2016
Same author

Ag-catalysed cutting of multi-walled carbon nanotubes.

Nanotechnology·2016
Same author

Beta Cell Regenerating Potential of <i>Azadirachta indica</i> (Neem) Extract in Diabetic Rats.

The West Indian medical journal·2015

Matrix metalloproteinases (MMPs) are enzymes involved in tissue remodeling and disease pathogenesis. Synthetic MMP inhibitors show promise in preclinical models and are advancing to human clinical trials for various conditions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes degrading extracellular matrix proteins.
  • MMPs play roles in normal tissue remodeling and disease pathogenesis, including cancer, rheumatoid arthritis, and multiple sclerosis.
  • Elevated MMP activity in malignancies correlates with poor prognosis, facilitating tumor invasion, metastasis, and angiogenesis.

Purpose of the Study:

  • To develop low molecular weight synthetic inhibitors targeting MMPs.
  • To evaluate the efficacy of these inhibitors in preclinical disease models.
  • To advance promising MMP inhibitors into clinical trials.

Main Methods:

  • Structure-based drug design was employed to create synthetic MMP inhibitors.

Related Experiment Videos

  • Inhibitor efficacy was assessed in relevant animal models of disease.
  • Several compounds (CGS 27023A, AG3340, Ro 32-3555, marimastat) progressed to clinical evaluation.

    • Main Results:

    • Low molecular weight synthetic MMP inhibitors were successfully developed.
    • These inhibitors demonstrated effectiveness in animal models of various diseases.
    • Multiple MMP inhibitors have entered human clinical trials.

    Conclusions:

    • Synthetic MMP inhibitors represent a promising therapeutic strategy.
    • Structure-based design is effective for developing potent MMP inhibitors.
    • Clinical trials are underway to assess the therapeutic potential of these inhibitors in humans.